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Abstract 
Retinal vascular diseases are a leading cause of blindness in the Western world. 
Advancement in the clinical management of these diseases has been fast-paced, with 
new treatments becoming available.  Eye care services account for nearly one in ten 
hospital outpatient appointments in England.  This paper discusses the development 
of a decision support toolkit (DST) that facilitates the improvement of retinal services 
by identifying cost savings and efficiencies within the pathway of care. The paper 
describes the development of the DST with the help of NHS and commercial experts 
in the retinal pathway.  The DST enables users to model their own services by 
working with the DST interface allowing them to specify local services.  Users can 
input local estimates or data of service demands and capacities thus creating a 
baseline discrete event simulation model. Users can then compare the baseline with 
potential changes in the patient pathway in the safety of a virtual environment. The 
tool enables key decision makers to estimate the likely impact of changes, such as 
increased use of new treatment vs. existing treatment regime.  By making such 
changes the impact on activity, cost, staffing levels, skill-mix and utilisation of 
resources can be easily understood. Such previously unobtainable quantitative 
information can be used to support business cases for change in retinal services. 
 
Keywords: Discrete event simulation, decision support toolkit, ophthalmology, retinal 
services and patient flow modelling. 
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1. Introduction 
Eye care services are provided in primary care and community settings such as high 
street optometrists, as well as acute hospitals. Eye services have a low profile, yet 
involve a high volume of work. They account for nearly one in ten hospital outpatient 
appointments (the second highest demand specialty with 5.95m ophthalmology 
attendances in 2009/10 in England) and 7-8% of all operations performed by the 
National Health Service (NHS), where demand has risen by 25% over seven years 
(UK Vision Strategy 2014).  
 
Most hospital activity in retinal services is accounted for by four conditions, all of 
which are expected to increase in prevalence as the population ages. These conditions 
are diabetic macular oedema (DMO), retinal vascular occlusions (RVO) and age-
related macular degeneration (AMD), which are all treated with retinal laser or 
injections.  The fourth condition is associated with surgical operations.  
 
DMO is a complication of diabetic retinopathy and a leading cause of blindness (Ford 
et al. 2013). The prevalence of DMO is likely to increase with more people suffering 
from diabetes (Holman et al. 2011). In 2010, the estimated healthcare costs for DMO 
in England were £92 million, with £65.6 million being spent on hospital treatment and 
related costs (Minassian, Owens and Reidy 2012). RVO is a blockage of the small 
veins that carry blood away from the retina, which is the second most common sight-
threating retinal vascular disorder after DMO (Laouri et al. 2011). There are two types 
of retinal vein occlusion: branch retinal vein occlusion or central retinal vein 
occlusion. AMD is an eye condition that affects a tiny part of the retina at the back of 
your eye for those aged over 50. AMD causes problems with your central vision, but 
does not lead to total loss of sight.  There are two types, wet AMD and dry AMD. 
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According to Owen et al. (2012) there are 513,500 prevalent cases of late AMD. 
Patients diagnosed with RVO, DMO and AMD are usually treated with an injection in 
to the eye with varying frequency.  If patients are left untreated, many eye conditions 
deteriorate rapidly. Early intervention can save sight or prevent further loss and allow 
people, many of them elderly, to maintain their independence. Delayed intervention 
can cost them their sight. Preserving or saving a person’s sight can reduce their risk of 
other adverse events, such as falling or becoming unemployed.  
 
The treatment of patients is resource intensive, requiring a multi-disciplinary team 
including radiologists, optometrists, specialist nurses, eye consultants and 
pharmacists.  Combining this with an increasingly aged population and increased life 
expectancy, it is clear that healthcare systems around the world will find the 
management of such patients more and more challenging. This will essentially create 
an increase in demand for this service, without consideration of the related increases 
across other areas of the healthcare system.  In England in particular, the National 
Health Service (NHS) is faced with additional pressures stemming from ever 
increasing resource and capacity constraints (e.g. reduction in budgets, fewer doctors 
and nurses, reduced number of hospital beds, etc.).  
 
In this context, there is growing evidence of financial pressures building in the NHS 
this year; 2015/16 has been cited as a possible financial ‘cliff edge’ as providers plan 
to cut emergency and other elective work as part of the opportunity cost of diverting a 
further £1.8 billion of NHS allocations to consolidate the £3.8 billion (The Kings 
Fund, 2014). There can be little doubt that the NHS faces an unprecedented resource 
challenge. Therefore, hospitals and commissioners of health services need to find 
effective and efficient ways of delivering services to achieve the best outcomes for 
ophthalmology patients who need care and support at all times. The key question is 
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where and how to make changes to ensure that care and support are delivered in an 
efficient and effective manner.  
 
In many respects, the solution may lie in redesigning retinal services (eye care 
services). This requires commissioners to develop a change programme in partnership 
with providers, local area teams (who commission primary care eye services), local 
health and wellbeing boards and other stakeholders. Often changes are introduced 
without proper consideration of the impact on the service. It is also often the case that 
those people working in the healthcare system know how they would like to improve 
the service they deliver, but lack the expertise to frame those improvements in a 
manner that will be acceptable to executives and holders of finance budgets. Thus 
there is a need for a decision support tool that captures the complexity in the system at 
a sufficient level and is user-friendly such that it can be easily understood and 
manipulated by end users. The tool should respond to the concerns of these end users 
and enable them to achieve a better understanding of the system structure and 
operations and how these influence key performance metrics, such as activity results 
(e.g. the number of patients treated per year), resource utilisation levels (e.g. eye 
consultants, nurses) and clinical and cost outcomes. In this context, the tool should 
accommodate the playing-out of a range of policies and scenarios relevant to decision 
makers and allow testing of the possible impact of these scenarios on the care system 
performance indicators. For example, the tool could determine the likely resource 
utilisation impact of a new policy whereby RVO patients are treated by a new 
treatment in the market (e.g. steroid), which may reduce the number of follow-up 
treatments and/or reviews. This could then enable the design of more pro-active and 
better-informed policies and help towards their integration into the commissioning 
process.  
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The current study has two objectives. Firstly, to explore the impact of a range of 
changes to the retinal services pathway using discrete event simulation (DES) and to 
explore the utility of this approach in this setting. Secondly, to develop a user friendly 
decision support toolkit (a further development on the DES model) with relevant 
simulation controls. The objective here is to enable users to interact with the model by 
allowing them to make necessary changes to the input parameters, so that the model is 
service specific with a customized set of results, focusing on activity, costing and 
resource utilization. These indicators are known to be valuable for key decision 
makers in the process of commissioning and re-designing services. This toolkit would 
provide the user with the ability to compare and contrast results from one scenario 
with another scenario with the results dependent on the variables specified by the 
user. We will experiment the impact of increasing the use of steroids in steps of 10% 
(and reduce conventional treatment accordingly) and evaluate the likely effect it has 
on activity, costing and staff utilisation (details in section 3).  
 
Discrete Event Simulation 
DES has the ability to model individual patients and their unique trajectories as they 
flow through the care system and to incorporate a large number of different patient 
attributes such as age, gender and disease stage. It allows for the running of the model 
over extended time horizons. Patients move through the model and they can 
experience events at any discrete point in time. Moreover, DES provides the 
flexibility to incorporate capacity and resource constraints explicitly and to capture 
the “competition” between competing modelled entities for access to limited 
resources (a comprehensive overview of DES is given by Banks (Banks et al. 2005) 
and others or Fishman (Fishman 2001). For a review of DES modelling in healthcare 
see Gunal and Pidd (Gunal and Pidd 2010). 
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In the next section, we illustrate a qualitative map portraying the inner workings of 
the retinal services pathway, model building assumptions and the input parameters. 
All results with model outputs and scenarios are discussed in Section 3. Finally, in 
section 4 we discuss the limitations, usefulness and implications in practice. 
 
2 Material and methods  
2.1 Additional setting description  
The first stage of the pathway mapping was to research the current practices within 
the industry, which occur for the particular disease being evaluated.  This included 
utilising publications from the industry, such as the National Institute of Clinical 
Excellence (NICE) and other sources of information, which are recognised within the 
industry.  This allowed a baseline plan of the treatment events and a range of what-if 
scenarios for a particular patient within the patient pathway.   
 
The second phase of the pathway mapping consisted of structured interviews with 
Ophthalmology nurses across a number of clinics between March and August 2014. 
The interviews were conducted ‘on line’ using WebEx technology to allow the 
interviewer to share a working diagrammatic representation of the pathway. The 
interviewer discussed each stage of the pathway with the interviewee taking account 
of the interviewee’s opinion and adjusting the pathway in ‘real time’ as comments 
were made. Once the interviewee was satisfied with the structure of the pathway, the 
interview was closed. The interviews were recorded so that the interviewer could 
review comments after the event to ensure that all salient points had been captured.  
In total six experts were interviewed iteratively.  The objective was to explore the 
Ophthalmology pathway in retinal services in order to establish what, in the experts’ 
opinion, important areas for development were.  They viewed the number of options, 
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which need to be static or variable for the simulation model to represent the possible 
scenarios which could be run by a clinic around the country.   
 
According to the interviews the typical care system in place in England and elsewhere 
for diagnosing, treating and looking after patients with problems in the eye comprises 
a complex set of services offered in and out of hospital. Examples of care services 
offered in hospital include emergency care, outpatient appointments with specialists 
such as specialist nurses, access to advanced diagnostic procedures such as 
ultrasound. 
 
Figure 1 shows diagrammatically the inner workings of the Ophthalmology pathway. 
Patients are referred to retinal services via their General Practitioner (GP) or 
community optometrists, and on a small number of occasions via accident and 
emergency (A&E) or outpatient services. Typically, 70% of patients are referred to a 
retinal service via their GP, 20% internal hospital referral and 10% through A&E. 
Patients first go through a number of check-ups at the initial assessment (or 1st 
outpatient appointment), which may include use of LogMAR charts to measure visual 
acuity; a slit lamp to see areas at the front of the eye, including the eyelids, 
conjunctiva, iris, lens, sclera and cornea; Optical coherence tomography (OCT) to 
study the structure of the eye in three dimensional space, and angiography to evaluate 
the blood flow through the vessels in the back of the eye. All patients would be 
subject to a LogMAR chart, around 70% OCT, 40% slit lamp and 2% angiography. 
 
After careful evaluation patients are diagnosed and categorised into AMD, DMO, 
RVO or no major diagnosis and placed into the observation category. The estimated 
prevalence and incidence of late stage AMD in the UK for a population greater or 
equal to 50 is 2.4% (Owen et al 2012). According to the Office of National Statistics 
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(ONS) mid-2013 population estimates 34% of UK population’s age is 50 or more 
(ONS 2014). When users specify their clinical commissioning group (CCG) 
population the expected number of AMD patients could easily be calculated, and 
therefore the number of patients routed out to AMD is determined. CCGs are groups 
of General Practitioners and from April 2013 they will be responsible for designing 
local health services in England. As RVO is made up of two categories and the 
prevalence and incidence rates are different, 0.5–2.0% for branch RVO and 0.1–0.2% 
for central RVO (Laouri et al 2011). At each run of the simulation the model 
randomly selects a number 0.5-2.0% for branch RVO and 0.1-0.2% for central RVO 
and calculates the number of RVO patients accordingly (again using the specified 
CCG population). Before we could calculate the number of DMO patients, we first 
need to determine the prevalence of diabetes in England and according to Diabetes 
UK (Diabetes UK 2013) it’s around 4.6% and the prevalence of DMO is estimated to 
be 7.12% (Minassian, Owens and Reidy 2012).  
 
Patients are referred to relevant treatment depending on their diagnosis. The choice of 
treatment varies considerably between providers. As a result, users are asked to 
specify the percentage of patients receiving best supportive care, laser treatment, 
AntiVegF (Anti vascular endothelial growth factor), steroids and photodynamic 
therapy (PDT). Anti-VEGF treatments are given by an injection into the eye and work 
by reducing the growth of new blood vessels and the oedema (swelling) they may 
cause. AntiVEGF agents include ranibizumab (Lucentis), bevacizumab (Avastin) and 
aylibercept (Eylea). Steroids are also injected into the eye to treat inflammation 
caused by disease, such as kenolog (Triamcinolone), fluocinolone (Illuvien), and 
ozurdex (dexamethasone).  
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If x percent of patients are referred to AntiVEGF treatment (typically around 64%), 
we then ask users to specify the percentage of patients on Lucentis (70%), Avastin 
(20%) and Eylea (10%).  Similarly, if y percent of patients are treated with steroids 
(around 5%), what percentage of patients are on Triamcinolone (10%), Illuvien (5%) 
and Ozurdex (85%)? Note that these percentages are based on the responses from 
nurse interviews, hence are bound to vary between retinal services. 
 
Once treatment commences patients have follow-up appointments to review their 
condition. Typically, patients would have as many follow-ups as treatment in the eye 
(injections). For instance, if a patient is on Avastin (an AntiVEGF treatment) then 
they are injected z times in the first year (with z follow-ups), s in the second year 
(with s follow-ups) and t in the third year (with t follow-ups). Similar information is 
entered for each treatment type to ensure that activities are modelled accurately within 
the simulation.        
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Figure 1 Conceptualised pathway for Ophthalmology patients. LogMar is logarithm of the minimum angle of resolution; OCT is optic 
coherence tomography; AMD is age-related macular degeneration; DMO is diabetic macular oedema; RVO is retinal vascular occlusions; 
AntiVegF is Anti vascular endothelial growth factor and PDT is photodynamic therapy.
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2.2 Input parameters  
Model inputs included staffing levels, staff salary, staff availability, treatment 
pathways, arrivals, discharges, percentage of patients falling into each treatment 
category, number of follow-ups, costing of each treatment, existing and new patient 
arrivals and treatment option visit parameters. The vast majority of input parameters 
are pre-determined through an in-depth review of the literature and expert opinions 
provided by the six specialist nurses. Note that all input parameters are pre-populated 
and can be changed by the service provider (or purchaser) if the users deem this to be 
necessary to fit their geographical area.   
 
The input parameters cover a range of areas for the Ophthalmology simulation model 
comprising demand, diagnosis, treatment, costing, and salary attributes.  The demand 
for the service takes in to consideration the population and the annual increase in 
patient numbers each year.  The prevalence and the incidence rate in the general 
population is as specified above. 
 
The treatment options for the service take into consideration the type of treatment 
provided to the patient, the length of treatment, the number of treatments (e.g. 
injections), the initial and follow up visits required dependent on patient type (AMD, 
RVO and DMO).  Further attributes include how much time is taken for the visits to 
occur, as well as the responsibility for each type of staff connected with such a visit.  
Each of these attributes is variable and can be determined by the user. The attributes 
are obtained through extensive research of the pathway and thorough detailed analysis 
of the treatment options which can be provided to an Ophthalmology patient.    
 
The costing options within the simulation model comprise the costs of initial and 
follow up visits and the hourly rate of staff within an Ophthalmology clinic, which are 
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determined by the Unit Cost of Health and Social Care 2013 (PSSRU 2013). In 
addition, drug costs are also included using British National Formulary (BNF) (BNF 
2014). All costing information can be overridden by the user. An initial visit costs 
around £106.  The hourly rates of staff at an Ophthalmology clinic are shown in Table 
1.  The unit cost of Avastin, Lucentis, Eylea, Ozurdex, Triamcinolone and Iluvien is 
£242.66, £742.17, £816, £870.00, £1.49 and £5,500, respectively. Users can easily 
specify the number of available resources within their retinal services to analyse the 
effects of increasing/decreasing resources. 
 
Table 1 Hourly rates of staff within an Ophthalmology clinic. GPwSI refers to 
General Practitioner with a Specialist Interest.  
Consultant £ 139.00  
Staff Grade/GPwSI £ 134.00  
SpR £ 71.00  
Optomotrist £ 67.00  
Nurse  £ 100.00  
Optician £ 22.00  
Technician £ 22.00  
Photographer £ 22.00  
Healthcare Assistant £ 21.00  
 
3 Illustrative Results 
 
According to the responses from the nurses approximately 64% of patients receive 
AntiVegF for the treatment of AMD, RVO and DMO (10% best supportive care, 20 
% laser, 5% steroids and 1% PDT). Of those on AntiVegF, 5%, 75% and 20% receive 
Avastin, Lucentis and Eylea, respectively, and of those on steroids, 85%, 10% and 5% 
receive Ozurdex, Kenolog and Illuvien, respectively.  Given that there are various 
treatment options, we seek to explore the impact of increasing the use of steroids in 
steps of 10% (and reduce AntiVegF accordingly) and evaluate the likely effect it has 
on activity, costing and staff utilisation. Note that this is solely for illustrative 
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purposes and no assumption is made in relation to the efficacy of medication, e.g., 
AntiVegF may have fewer side effects compared to steroids (or vice or versa).  
However, we assumed that AntiVegF have the same beneficial effect as steroids. 
 
We also asked nurses about the frequency of use of medication (i.e. the average 
number of injections per year per patient), to establish the activity associated with 
visiting outpatient clinics (see Table 2).  Patients (particularly the elderly) are usually 
treated over a three year cycle; hence in a given year our model should separate new 
patients from existing patients, where the existing ones could either be in their second 
or third year of treatment. From the interviews, 70%, 20% and 10% of patients are 
new, second and year third year of treatment, respectively.      
 
Table 2 Average number of visits to the outpatient clinic for injections in the eye per 
year per patient according to treatment type 
Drug  Frequency of use in the 
first year (i.e. the average 
number of injections) 
Frequency of use in the 
second year (i.e. the average 
number of injections) 
Avastin 5 3 
Lucentis 7 4 
Eylea 7 4 
Ozurdex 2 1 
Kenolog 2 1 
Illuvien 1 0 
 
The model was populated with a population of 250,000 (a typical size of a clinical 
commissioning group in England) at the beginning of year 1. Based on this population 
and the prevalence and incidence statistics specified above for RVO, DMO and AMD, 
the estimated number of patients treated within retinal services is 4,359.  
 
The simulation was run for three years to capture the individual trajectories in the 
cohort over this period and to estimate the likely impact of changes in performance 
indicators. The number of patients requiring treatment, which determines the level of 
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demand on care services, is not constant over time but has an upward trend. The 
model captures this aspect through the year-to-year percentage increase in the number 
of patients in the service. The data for the yearly increase in arrivals is user specified 
and as such, is determined by the values the user has entered (in this context a 1% 
increase is projected).  
 
The model was run for a simulation period of 3 years with a warm up period of 1 year 
determined using the Welch method (Law and Kelton 2000) to make sure that the 
results were not collected until all patients in the cohort had gone through the care 
system. The weekly simulation period was Monday to Friday from 9am to 5pm 
reflecting the current operating arrangements in retinal services.   
 
3.1 Model Validation 
 
The model validation process was carried out by comparing the expected number of 
activity results over a 3-year period using the known data in the actual care system 
with the simulation results. As described in the previous section, the total patient 
population size is expected to reach 4,491 by the end of year 3 (1% increase each 
year). The total number of visits over a 3-year period was calculated taking into 
account the total cohort size, the number of DMO, RVO and AMD patients, the 
average number of injections (for each drug type) and follow-up visits per year for 
each patient type, and the simulation duration of 3 years. The difference between the 
real life calculations and the simulation model has been within the confidence interval 
range of 95%, giving a result from the model, which is within 5% either side of the 
expected result.  This deems the model suitable to allow further experimentation with 
other scenarios. 
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To achieve face validity, the model was shown to each nurse individually and then in 
a workshop including all six nurses. The model structure was confirmed to be highly 
representative of the real world retinal care services by all six nurses in the individual 
meetings and during the workshop where the whole group was present. In general, the 
continuous engagement of the nurses throughout the study significantly increased 
confidence in the validity of the model.  
 
3.2 Experimentation 
The aim of the experiment is to explore the impact of increasing the use of steroids in 
steps of 10% (and reduce AntiVegF accordingly), keeping the number of treatments 
and the percentage of patients on Avastin, Lucentis, Eylea (AntiVegF) and Ozurdex, 
Kenolog, Illuvien (steroids) the same and evaluate the likely effect it has on activity 
and costing (see Table 3 for the list of experiments). The tool enables users to input 
parameters for two sets of scenarios, the first for the baseline model (existing service) 
and the second for experimentation. Therefore, all input parameters can be customised 
for both scenarios.  
 
Table 3: Scenario analysis based on decreasing use of AntiVegF in steps of 10%  
Treatment type Baseline 
(% of 
patients 
receiving) 
Experiment 1 
(% of patients 
receiving) 
Experiment 2 
(% of patients 
receiving) 
Experiment 3 
(% of patients 
receiving) 
Experiment 4 
(% of patients 
receiving) 
Best Supportive 
Care 
10 10 10 10 10 
Laser 20 20 20 20 20 
Anti VegF 64 54 44 34 24 
Steroid 5 15 25 35 45 
PDT 1 1 1 1 1 
Total 100 100 100 100 100 
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Note that the experiments presented below do not consider the efficacy and side 
effects of AntiVegF and steroids, it is a purely an experimentation based on various 
“what if scenarios”, to showcase some of the features of the decision support tool.   
According to Figures 2 and 3 reducing AntiVegF (and increasing steroids) by 10% 
has a significant impact on activity and costing. For instance, a comparison between 
the baseline model (64% on AntiVegF and 5% steroids) and experiment 3 (34% 
AntiVegF and 35% steroids) shows a dramatic reduction in the number of treatments, 
that is 17,134 and 9,118 injections  in year 1, respectively (see Table 4). The decrease 
is due to the fact that the average number of injections administered in a year for 
steroids is less than AntiVegF (based on nurse interviews). Furthermore, we also 
notice a reduction in drug costs from £13,025,750 to £6,919,311 (in year 1) and the 
knock on effect on total costing of the entire pathway (including drug, staff and other 
costs) is a reduction from £13,349,762 to £8,844,221. An interesting insight is the 
reduction in outpatient visits, which are primarily made up of follow-ups, from 19,508 
(baseline year 1) to 13,322 (experiment 3), again due to less follow-ups for those on 
steroids.  
 
According to nurse interviews a typical retinal service may have five consultants (or 
specialist) which may vary considerably depending on geographical region of the 
clinic and specialisation. The experimented changes seem to have no effect on 
consultant’s service hours.  The total number of service hours to treat all patients 
(where a consultant is involved) is around 2,500 hours per year (see Figure 4), which 
is equivalent to 0.3 full time equivalent of a consultant time, that is, each of the five 
consultants would spend around 30% of their time treating patients.  
 
There is a noticeable small variation in activity across the years and the reason for this 
is that we assumed the number of times a patient visits a clinic for treatment is fixed  
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(according to the interviews we had with the nurses, see Table 2), hence no 
distributional assumptions were made on these treatment types. This small variation is 
caused by the number of “new” arrivals each year during simulation run.  
 
Note that the model is not limited to these outputs, it’s developed to generate a series 
of key performance metrics, reporting scenario 1 and scenario 2 (for each of the three 
years) with respect to arrivals; diagnosis process (LogMAR charts, slit lamp, OCT 
and angiography); treatment process (e.g. follow-ups, treatment type, number of 
injections, etc.); financial reporting of all activities in the diagnosis and treatment 
phase; and staff utilisation in terms of service hours and full time equivalent needed to 
ensure services are provided efficiently and effectively.  
 
Table 4: The impact of decreasing the use of AntiVegF on activity and costing  
  
AntiVegF Steroids Total number 
of outpatient 
visits 
Total Cost 
of pathway 
Activity Costing Activity Costing 
Baseline 
Year 1 17,134 £13,025,750 372 £324,012 19,508 £13,349,762 
Year 2 17,317 £13,134,719 376 £327,496 19,720 £13,462,215 
Year 3 17,080 £12,936,778 376 £327,496 19,463 £13,264,274 
Experiment 1 
Year 1 14,593 £11,059,365 1,010 £879,710 17,518 £11,939,075 
Year 2 14,698 £11,164,928 908 £790,868 17,676 £11,955,796 
Year 3 14,730 £11,189,297 995 £866,645 17,758 £12,055,942 
Experiment 2 
Year 1 11,669 £8,852,070 1,600 £1,393,600 15,260 £10,245,670 
Year 2 11,895 £9,027,767 1,639 £1,427,569 15,506 £10,455,336 
Year 3 12,139 £9,214,648 1,613 £1,404,923 15,770 £10,619,571 
Experiment 3 
Year 1 9,118 £6,919,311 2,210 £1,924,910 13,322 £8,844,221 
Year 2 9,175 £6,970,528 2,253 £1,962,363 13,378 £8,932,891 
Year 3 9,451 £7,149,988 2,288 £1,992,848 13,807 £9,142,836 
Experiment 4 
Year 1 6,534 £4,995,210 2,871 £2,500,641 11,383 £7,495,851 
Year 2 6,412 £4,866,675 2,936 £2,557,256 11,369 £7,423,931 
Year 3 6,735 £5,093,139 2,824 £2,459,704 11,591 £7,552,843 
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Figure 2: The impact of decreasing AntiVegF and increasing Steroids in steps of 10% 
on activity (the number of treated patients and outpatient visits) 
 
 
Figure 3: The impact of decreasing AntiVegF and increasing Steroids in steps of 10% 
on costing (total costing includes the cost of diagnosis, treatment, staff and 
medication).   
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Figure 4: Consultant service hours (baseline vs. experiment 4)   
 
 
4 Discussion  
The authors are aware of the many difficulties that are faced in the planning and 
approving of new healthcare services. Changes can be introduced without proper 
consideration of the impact on the service. Frequently people working in the 
healthcare system know how they would like to improve the service they deliver, but 
lack the expertise to frame those improvements in a manner that will be acceptable to 
executives and holders of finance budgets. This tool was developed, in conjunction 
with specialists in the retinal pathway, specifically to address these issues. It is 
designed to allow ‘non-experts’ to test change on the pathway within the validated 
simulation.  The simulation will present the impact of changes in a way that can be 
easily understood by both the executives and the pathway specialists. The intention is 
that this will facilitate service planning and decision making and speed up the pace of 
change in the ophthalmology pathway. 
 
This simulation is currently being used nationally by a major pharmaceutical 
company, who also supply some of the drugs in the pathway, to facilitate service 
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change in the UK. The pharmaceutical company’s healthcare development team are 
working with providers to improve services and health outcomes for retinal patients.  
 
The choice of using simulation methods as opposed to analytical methods was partly 
dictated by the complexity of the pathway and the ease of use for end-users. In this 
respect, the need to track individual patient journeys (or trajectories) through the care 
system, the ability to capture the complex web of interactions of patients going 
through the diagnosis stage to various forms of treatment (including follow-ups) and 
the need to model notions of limited availability of resources (such as staff) have 
motivated us to select DES. Furthermore, DES enables user to take their pathway 
beyond flow-diagram drawings (i.e. the conceptualised pathway with experts) by 
using the animation features offered by SIMUL8, which allows you to see your 
patient pathway actually running. We developed a view of the operations from 
various angles and levels of magnification. This allowed users to detect design flaws 
that appear credible when seen just on paper in a 2-D drawing.   
 
The tool allows decision makers to better understand the operation of the system in 
relation to key performance metrics associated with activity, cost implications and 
resource utilisation. The ease of use of the tool with relevant sets of exported results 
means that senior decision makers can be more proactive with evidence based 
approach in re-designing their care pathway in finding the most efficient and effective 
delivery of care to patients with problems in the eye.  
 
There is an increasing need to improve efficiency and effectiveness in health care 
delivery.  However complexities in the delivery of services present commissioners 
with significant challenges.  The development of a simulation based DSS enables a 
wide variety of scenarios to be tested and the impact on performance indicators to be 
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easily evaluated, offering commissioner’s huge potential to experiment with change in 
the safety of a virtual environment. 
 
The simulation results suggest that an increased use of steroids will have a positive 
impact on the workload (i.e. number of injections and outpatient visits) and costing. 
The policy rationale follows that reducing the number of unnecessary visits to hospital 
without affecting the quality of treatment (more importantly the outcome on patients), 
is strongly supported by the simulation results. As such, the simulation based DSS 
developed here is a very good example of the “evidence based decision making” 
tools, which have gained in popularity in the last few years, especially within the 
healthcare management sector. Although the changes have implied a decrease in 
activity and costing (hence the opportunity to allocate resources to other areas of 
need), there are no changes to consultant service hours. 
 
A limitation of the study is that we did not take account of co-morbidities and 
interactions with other diseases (e.g. diabetes) which may impact on the speed of 
disease progression and the associated level of care. The model was built using 
information from a single context, which can “corrupt” the results and reduce 
confidence in the validity of the results and the ensuing policy decisions. Furthermore, 
some of the input parameters (e.g. percentage of patients on AntiVegF and steroids, 
and frequency of treatment) were determined by asking nurses during the interviews. 
However, a data driven approach would have made our model and findings more 
robust and accurate by identifying the distribution for each treatment type (i.e. 
frequency of use of treatment) as opposed to using a fixed value.  
 
The main strength of this decision support tool is the adoption of a team approach to 
studying the system, involving six specialist nurses across the country, ensuring that a 
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variety of views and suggestions were taken as well as systems modelling and 
simulation. This led to a model with high face validity and credibility among its users. 
Future work could explore additional ways in which the current model could 
incorporate individual patient characteristics (e.g. disease severity, age group, gender, 
etc.), which may alter patients pathway and explore the impact on activity results and 
costing. Furthermore, the evaluation of performance would be more realistic if it 
included performance indicators related to the quality of care and its impact on the 
quality of life of patients, and investigated how these aspects may affect readmission 
and mortality and the movement of patients between the different care services within 
the pathway.  
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